Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer

Immunotherapy

Volumn 3, Issue 7, 2011, Pages 805-807

  Goyne, Hannah ^a   Stone, Pamela J B ^a   Cannon, Martin J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

adjuvants; dendritic cells; ovarian cancer; Th17 cells; tumor vaccines

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; IMATINIB; PAMIDRONIC ACID; ZOLEDRONIC ACID;

FOOD AND DRUG ADMINISTRATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH17 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS, ALKYLATING; CANCER VACCINES; CLONAL ANERGY; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; IMMUNOSUPPRESSION; IMMUNOTHERAPY, ACTIVE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MACROPHAGES; NEOPLASMS; OVARIAN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1;

EID: 79960527435     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.71     Document Type: Review

References (21)

1. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004).
2. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002).
3. Curiel TJ, Wei S, Dong H, Alvarez X et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9(5), 562-567 (2003).
4. + regulatory T cells. Proc. Natl Acad. Sci. USA 105(27), 9331-9336 (2008).
5. + T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 104(9), 3360-3365 (2007).
6. Kryczek I, Wei S, Zhu G et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67(18), 8900-8905 (2007).
7. Okamoto A, Nikaido T, Ochiai K et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 11(16), 6030-6039 (2005).
8. Inaba T, Ino K, Kajiyama H et al. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol. Oncol. 115(2), 185-192 (2009).
9. Chung DJ, Rossi M, Romano E et al. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 114(3), 555-563 (2009).
10. + Tregs to Th17-like cells in tumor-draining lymph nodes. Blood 113(24), 6102-6111 (2009).
11. Baban B, Chandler PR, Sharma MD et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 183(4), 2475-2483 (2009).
12. Kryczek I, Banerjee M, Cheng P et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114(6), 1141-1149 (2009).
13. Munn DH. Th17 cells in ovarian cancer. Blood 114(6), 1134-1135 (2009).
14. Cannon MJ, Goyne H, Stone PJB, Chiriva-Internati M. Dendritic cell vaccination against ovarian cancer - tipping the Treg/ Th17 balance to therapeutic advantage? Exp. Opin. Biol. Ther. 11(4), 1-5 (2011).
15. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppresso T cells. J. Exp. Med. 155(4), 1063-1074 (1982).
16. Viaud S, Flament C, Zoubir M et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 71(3), 661-665 (2011).
17. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11(18), 6713-6721 (2005).
18. Mukherjee P, Basu GD, Tinder TL et al. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J. Immunol. 182(2), 216-224 (2009).
19. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 67(23), 11438-11446 (2007).
20. Tsagozis P, Eriksson F, Pisa P. Zoledronix acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol. Immunother. 57(10), 1451-1459 (2008).
21. Coscia M, Quaglino E, Iezzi M et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J. Cell. Molec. Med. 14(12), 2803-2815 (2010).